Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: A randomised controlled study

Abstract

Flutamide and spironolactone plus CPA/EE are effective drugs in the treatment of hirsutism.

Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: A randomized controlled trial

“…In terms of hirsutism, both OCP plus spironolactone and OCP containing CPA do not seem to be strong regimens for 3 months of treatment. Although some authors could show a significant decrease in hirsutism scores from 3 months of therapy, most studies have demonstrated that OCP with and without combination of other medicines are effective after 6 months of treatment . Although the hirsutism score was significantly decreased after 3 months of OCP with CPA usage, it may have no clinical significance in the current study.…”

“…Although some authors could show a significant decrease in hirsutism scores from 3 months of therapy, 35 most studies have demonstrated that OCP with and without combination of other medicines are effective after 6 months of treatment. [36][37][38] Although the hirsutism score was significantly decreased after 3 months of OCP with CPA usage, it may have no clinical significance in the current study. The mean initial and post-treatment mF-G scores were much lower than that of the definition of hirsutism, consistent with the fact that hirsutism is not common in Thai PCOS women.…”

Reduction of Diameter of Hair Shaft among Women with Hirsutism

“…A Cochrane review 2009 ( (Brown et al, 2009) of nine randomized controlled intervention, two trials that compared 6 months treatment of 100mg /d of spironolactone with placebo was associated with a statistically significant subjective improvement in hair growth and a decrease in Ferriman-Gallway scores (F-G), similar finding also had been revealed in other studies conducted by (Karakurt et al, 2008) and a study conducted by Poll Mara (Spritzer et al, 2000) using the same subjective clinical parameter.…”

Polycystic Ovary Syndrome

“…Spironolactone is a potassium-sparing diuretic that is used in PCOS to treat the effects of excessive androgen in women. 44,[55][56][57][58] Spironolactone inhibits the effects of aldosterone in the distal renal tubules and acts as an androgen receptor blocker interfering with steroid synthesis. Clinically, this medication has been used in patients with PCOS to effectively reduce androgen-mediated symptoms while restoring ovulation and menstrual flow.…”